Christopher H. van Dyck
Anavex's Blarcamesine Cuts Alzheimer's Progression by 20 Months in Phase IIb/III Trial
100% left coverage1 source
Discover the latest news, candidates, and key topics of US politics
Discover the latest news, candidates, and key topics of US politics